Dentinogenesis imperfecta type 2

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:166260OMIM:125490K00.5
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Dentinogenesis imperfecta type 2 (DGI-II), also known as hereditary opalescent dentin, is a genetic disorder affecting the dentin — the hard tissue that forms the bulk of the tooth beneath the enamel. It is the most common hereditary disorder of dentin and is caused by mutations in the DSPP (dentin sialophosphoprotein) gene located on chromosome 4q22.1. DGI-II affects both the primary (baby) and permanent teeth, though primary teeth are typically more severely affected. Clinically, teeth affected by DGI-II have a characteristic translucent or opalescent appearance, ranging in color from amber to blue-gray or brownish. The enamel, although structurally normal, tends to chip away easily from the abnormal underlying dentin, exposing the softer dentin to rapid wear and attrition. The dentin itself is poorly mineralized and disorganized, and the pulp chambers of the teeth are often obliterated (sclerosed) over time. Patients may experience significant tooth wear, fractures, and early tooth loss. Unlike dentinogenesis imperfecta type 1, DGI-II occurs as an isolated dental condition without associated bone fragility or osteogenesis imperfecta. There is currently no cure for DGI-II. Treatment is focused on preserving tooth structure, preventing excessive wear, and maintaining dental function and aesthetics. Management strategies include the use of stainless steel crowns or full-coverage restorations in children to protect primary teeth, composite or porcelain restorations for permanent teeth, and in severe cases, overdentures or dental implants in adulthood. Early dental intervention and regular follow-up with a pediatric dentist or prosthodontist are essential to optimize outcomes and quality of life.

Also known as:

Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Dentinogenesis imperfecta type 2.

View clinical trials →

No actively recruiting trials found for Dentinogenesis imperfecta type 2 at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Dentinogenesis imperfecta type 2 community →

No specialists are currently listed for Dentinogenesis imperfecta type 2.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Dentinogenesis imperfecta type 2.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Dentinogenesis imperfecta type 2Forum →

No community posts yet. Be the first to share your experience with Dentinogenesis imperfecta type 2.

Start the conversation →

Latest news about Dentinogenesis imperfecta type 2

No recent news articles for Dentinogenesis imperfecta type 2.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Dentinogenesis imperfecta type 2

What is Dentinogenesis imperfecta type 2?

Dentinogenesis imperfecta type 2 (DGI-II), also known as hereditary opalescent dentin, is a genetic disorder affecting the dentin — the hard tissue that forms the bulk of the tooth beneath the enamel. It is the most common hereditary disorder of dentin and is caused by mutations in the DSPP (dentin sialophosphoprotein) gene located on chromosome 4q22.1. DGI-II affects both the primary (baby) and permanent teeth, though primary teeth are typically more severely affected. Clinically, teeth affected by DGI-II have a characteristic translucent or opalescent appearance, ranging in color from amber

How is Dentinogenesis imperfecta type 2 inherited?

Dentinogenesis imperfecta type 2 follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Dentinogenesis imperfecta type 2 typically begin?

Typical onset of Dentinogenesis imperfecta type 2 is childhood. Age of onset can vary across affected individuals.